期刊文献+

奥沙利铂联合替吉奥或卡培他滨方案用于胃癌术后疗效对比 被引量:18

Efficacy Comparison of SOX and XELOX Chemotherapy in Used after Gastric Cancer Operation
下载PDF
导出
摘要 目的观察并比较奥沙利铂联合替吉奥或卡培他滨方案在胃癌术后辅助化学治疗中的应用效果。方法将2010年1月至2015年1月收治的老年晚期胃癌初治患者70例,随机分为SOX组(奥沙利铂+替吉奥)和XELOX组(奥沙利铂+卡培他滨),各35例。结果70例患者共治疗327个周期。SOX组治疗167个周期,XELOX组治疗160个周期。SOX组的有效率为62.86%,XELOX组的有效率为51.43%。SOX组的生活质量改善率为85.71%,XELOX组的改善率为65.71%。SOX组较XELOX组不良反应发生率较小。结论 SOX方案比XELOX方案更适合治疗老年晚期胃癌。 Objective To compare the efficacy and adverse reactions of SOX and XELOX chemotherapy used after gastric cancer operation. Methods 70 cases of elderly patients with advanced gastric cancer in the hospital from January 2010 to January 2015 were randomly divided into two groups,35 cases of SOX group,35 cases of XELOX group. Results 70 patients were treated with 327 cycles.SOX group therapy had 167 cycles,XELOX treatment group had 160 cycles. The effectiveness of SOX and XELOX group was 62. 86%,51. 43% respectively. The quality of life improvement rate of SOX and XELOX group was 85. 71%,65. 71% respectively. The incidence of adverse reactions of SOX group was smaller than XELOX group. Conclusion The SOX program is more suitable than XELOX program for the treatment of elderly patients with advanced stomach cancer.
作者 胥敏
出处 《中国药业》 CAS 2016年第1期103-105,共3页 China Pharmaceuticals
关键词 晚期胃癌 替吉奥 奥沙利铂 卡培他滨 化学治疗 advanced gastric carcinoma S-1 oxaliplatin capecitabine chemotherapy
  • 相关文献

参考文献6

二级参考文献53

  • 1孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生社出版.2007.152.
  • 2Park YH,Kim BS,Ryoo BY,et al. A phase Ⅱ study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer [J]. Br J Cancer, 2006,94 (7) : 959-963.
  • 3Glimelius B,Ekstrom K,Hoffman K,et al. Randomized comparison between chemotherapy plus best supportive care with bestsupportive care in advanced gastric cancer [J]. Ann Oncol, 1997,8(2) : 163-168.
  • 4Casaretto L,Sousa PL, Mari JJ. Chemotherapy versus support cancer treatment in advanced gastric cancer:ameta-analysis [J]. Braz J Med Bicl Res, 2006,39 (4) : 431-440.
  • 5Maehara Y. S-1 in gastric cancer:a comprehensive review [J]. Gastric Cancer,2003,6(Suppl 1 ) :2-8.
  • 6Sakuramoto S ,Sasako M ,Yamaguchi T,et ah Adjuvant chemotherapy for gastric cancer with S-1 ,an oral fluoropyrimidine [J]. N Engl J Med, 2007,357(18) : 1810-1820.
  • 7Koizumi W,Narahara H,Hara T,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial) : a phase Ⅲ trial [J]. Lancet Oncol,2008,9(3):215-221.
  • 8Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69.
  • 9Zhao JG,Qiu F,Xiong JP,et al.A phaseⅡstudy of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer[J].Anticancer Drugs,2009,20(4):281.
  • 10Webb A,Cunningham D,Scarffe JH,et al.Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer[J].J Clin Oncol,1997,15(1):261.

共引文献69

同被引文献178

引证文献18

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部